anastrozole

We present a case of a 59-year-old postmenopausal female with metastatic hormone receptor-positive breast cancer who started treatment with fulvestrant and ribociclib after progression on anastrozole...Ribociclib was held, and after no improvement in 28 days, she was treated with a 6-day course of prednisone 1 mg/kg, with significant improvement in her liver enzymes...Following normalization of her liver enzymes, she was rechallenged with abemaciclib with no recurrent hepatotoxicity. Ribociclib hepatotoxicity can be successfully treated with withdrawal of the medication and a short course of corticosteroids if liver enzymes do not improve following a 28-day withdrawal, highlighting a potential immune-mediated mechanism. Additionally, rechallenge with another cyclin-dependent kinase 4 and 6 inhibitor is a safe and effective strategy that should be considered.

This prespecified 5-year follow-up of efficacy outcomes from NATALEE demonstrated that ribociclib + NSAI continued to reduce the risk of recurrence beyond the 3-year treatment window, supporting its use as adjuvant therapy in patients with HR-positive/HER2-negative EBC. An ongoing positive trend for improved OS in favor of ribociclib + NSAI was observed.

In both pre- and postmenopausal women, there is no difference in 10-year OS or LR between anastrozole and tamoxifen for BC patients with low Oncotype RS. We conclude that Stage 1-3, T1-T3 pre- and postmenopausal BC patients with Oncotype RS between 0 and 17 can safely choose either medication. This finding is of particular importance for premenopausal women who wish to avoid the adverse side effects of medically induced menopause and bone deterioration associated with the anastrozole and ovarian suppression approach.

The patient developed a grade 3 eruptive, maculopapular dermatitis to exemestane and subsequently letrozole. Unusually, a third AI - anastrozole - has been well tolerated. Severe dAEs secondary to AIs are rare, and there is a lack of evidence-based research to guide management of these reactions.

P=N/A, N=1, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | N=5087 --> 1

P3, N=1017, Completed, UNICANCER | Active, not recruiting --> Completed

P3, N=920, Recruiting, Eli Lilly and Company | Not yet recruiting --> Recruiting

P=N/A, N=3883, Active, not recruiting, Brigham and Women's Hospital

P=N/A, N=30, Not yet recruiting, Harbin Medical University Affiliated Cancer Hospital; Harbin Medical University Affiliated Cancer Hospital

Xentuzumab + abemaciclib + ETs demonstrated manageable tolerability and promising efficacy, especially in patients with breast cancer and non-visceral metastases.

She was treated with neoadjuvant anastrozole, modified radical mastectomy, adjuvant chemotherapy, radiation, and continued endocrine therapy...The disease progressed on fulvestrant and palbociclib, but switching to carboplatin, gemcitabine, and pembrolizumab led to rapid improvement: liver function normalized and imaging showed near-complete response within 3 months...This case explains the potential role of ICIs in HR+/HER2- breast cancer with unusually high PD-L1 expression. It underscores the importance of biomarker-driven treatment and supports expanding PD-L1 testing to better identify patients who may benefit from immunotherapy in this traditionally resistant subtype.

P=N/A, N=5087, Recruiting, Pfizer | Active, not recruiting --> Recruiting